Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis - Seite 2
Michael Rosol, Chief Medical Officer for Navidea, said, “These results support our hypotheses for Arms 1 and 2 of this trial and are key for the path forward to the Phase 3. The demonstration that Tc 99m tilmanocept imaging is stable and has low variability enables us to proceed with confidence in testing our hypothesis that this can be an early indicator of therapeutic efficacy in these patients.” Dr. Rosol continued, “With these exciting results in hand, we continue to enroll subjects as planned to complete this Phase 2B and prepare for the upcoming Phase 3.”
Jed Latkin, Navidea’s Chief Executive Officer, said, “I am very pleased that the results of this interim analysis are so encouraging. It reaffirms that we are heading in the right direction with our clinical trial pipeline in rheumatoid arthritis. I look forward to continuing this momentum into the Phase 3.”
RA is a chronic disease affecting over 1.3 million Americans and as much as 1% of the worldwide population.1 If the product is successfully developed, Navidea would expect to play a major role in the management of RA patients worldwide.
Conference Call Details
Investors and the public are invited to dial into a conference call through the information listed below, or participate via the audio webcast on the company website. Participants who would like to ask questions during the question and answer session will be prompted by the moderator, who will provide instructions.
Event: |
Results of Interim Analysis of Phase 2B Study in Rheumatoid Arthritis Conference Call |
|
Date: |
Tuesday, October 29, 2019 |
|
Time: |
5:00 p.m. (EDT) |
|
U.S. & Canada Dial-in: |
877-407-0312 |
|
International Dial-in: |
|
+1 201-389-0899 |
Conference ID: |
13696293 |
Webcast Link: https://webcasts.eqs.com/navidbioph20191029/en
The recorded conference call can be replayed and will be available for 90 days following the call, available on the investor relations page of Navidea’s corporate website at www.navidea.com.